

REVIEW

Open Access

Biology and pathophysiology of the amyloid precursor protein

Hui Zheng^{1*} and Edward H Koo²

Abstract

The amyloid precursor protein (APP) plays a central role in the pathophysiology of Alzheimer's disease in large part due to the sequential proteolytic cleavages that result in the generation of β -amyloid peptides ($A\beta$). Not surprisingly, the biological properties of APP have also been the subject of great interest and intense investigations. Since our 2006 review, the body of literature on APP continues to expand, thereby offering further insights into the biochemical, cellular and functional properties of this interesting molecule. Sophisticated mouse models have been created to allow in vivo examination of cell type-specific functions of APP together with the many functional domains. This review provides an overview and update on our current understanding of the pathobiology of APP.

Introduction

Alzheimer's disease (AD) is the most common cause of dementia and neurodegenerative disorder in the elderly. It is characterized by two pathological hallmarks: senile plaques and neurofibrillary tangles, as well as loss of neurons and synapses in selected areas of the brain. Senile plaques are extracellular deposits composed primarily of amyloid β -protein ($A\beta$), which is a 40-42 amino acid long peptide derived by proteolytic cleavages of the amyloid precursor protein (APP), with surrounding neuritic alterations and reactive glial cells. $A\beta$ has taken a central role in Alzheimer's disease research for the past two decades in large part because of the amyloid cascade hypothesis which posits that $A\beta$ is the common initiating factor in AD pathogenesis. Because of this, the processing of APP and generation of $A\beta$ from APP have been areas of substantial research focus by a large number of laboratories. By comparison, whether full-length APP or other non- $A\beta$ APP processing products play a significant role in AD or contribute to other neurological disorders has received somewhat less consideration. For example, it is unclear if the mutations in the APP gene found in the hereditary form of familial AD and the related hereditary amyloid angiopathy with cerebral hemorrhage (<http://www.molgen.ua.ac.be/ADMutations/>) are pathogenic solely because of perturbed $A\beta$ properties. However,

increasing evidence supports a role of APP in various aspects of nervous system function and, in view of the recent negative outcome of clinical trials targeting $A\beta$ production or clearance, there is renewed interest in investigating the physiological roles of APP in the central nervous system (CNS) and whether perturbation of these activities can contribute to AD pathogenesis.

This review will update some of the recent findings on the physiological properties of APP. We start with a general overview of APP. Because APP consists of multiple structural and function domains, we will focus our review by addressing the properties of the full-length APP as well as APP extracellular and intracellular domains. Finally, we provide an update on the current knowledge concerning the APP function in vivo, especially recent findings from the APP conditional knockout mice and knock-in alleles expressing various APP domains. For discussions on the pathophysiology of $A\beta$, there are many excellent reviews that summarize this area in detail but is otherwise beyond the scope of this article.

A. APP Overview

a) The APP Family

APP is a member of a family of conserved type I membrane proteins. The APP orthologs have been identified in, among others, *C. elegans* [1], *Drosophila* [2,3], Zebrafish [4] and *Xenopus Laevis* [5,6]. Three APP homologs, namely APP [7,8], APP like protein 1 (*APLP1*) [9] and 2 (*APLP2*) [10,11], have been identified in mammals (Figure 1). These proteins share a conserved structure

* Correspondence: huiz@bcm.edu

¹Huffington Center on Aging and Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
Full list of author information is available at the end of the article




Figure 1 Comparison of protein sequences of *C. elegans* APL-1, *Drosophila* APPL, Zebrafish APPa, Xenopus APP-A and the human APP, APLP1 and APLP2. Purple sequences indicate identical homology while green references similar amino acids. Homologous regions include the E1 domain (light blue line), E2 domain (yellow line) and sequences within the C-terminus such as the conserved Thr site (arrow head) and YENPTY motif (black box). The transmembrane domain and Aβ sequence are noted by the blue and red boxes respectively.

with a large extracellular domain and a short cytoplasmic domain. There are several conserved motifs, including the E1 and E2 domains in the extracellular region and the intracellular domain, the latter exhibiting the highest sequence identity between APP, APLP1 and APLP2. Of interest, the A β sequence is not conserved and is unique to APP. Additionally, the *APP* and *APLP2* genes, but not *APLP1*, were identified in *Xenopus Laevis*, suggesting that the first gene duplication resulted in *APP* and pre-*APLP* in the evolution of the *APP* superfamily, prior to the separation of mammals and amphibians [12]. Thus, *APLP1* diverged from the *APLP2* gene such that *APLP1* does not contain two additional exons present in both *APP* and *APLP2*, one of which encodes a Kunitz-type protease inhibitor domain. With this history, it is not surprising that *APLP1* is found only in mammals and, unlike *APP* and *APLP2*, it is expressed only in brain. However, given the sequence identity between the three genes, it is also not unexpected that the mammalian APP homologs play redundant activities in vivo (discussed in "The in vivo Function of APP"). The functional conservation of APP across species is also documented by the partial rescue of the *Drosophila Appl* null behavioral phenotype by human APP [3]. These observations indicate that the conserved motifs, rather than the non-conserved A β sequence, likely underline the physiological functions among the APP species.

b) APP Expression


The mammalian APP family of proteins is abundantly expressed in the brain. Similar to *Drosophila Appl* [13], *APLP1* expression is restricted to neurons. However, although highly enriched in the brain, *APP* and *APLP2* are ubiquitously expressed outside of the brain. The human *APP* gene, located on the long arm of chromosome 21, contains at least 18 exons [14,15]. Alternative splicing generates APP mRNAs encoding several isoforms that range from 365 to 770 amino acid residues. The major A β peptide encoding proteins are 695, 751, and 770 amino acids (referred to as APP695, APP751 and APP770). APP751 and APP770 contain a domain homologous to the Kunitz-type serine protease inhibitors (KPI) in the extracellular sequences, and these isoforms are expressed in most tissues examined. The APP695 isoform lacks the KPI domain and is predominately or even exclusively expressed in neurons and accounts for the primary source of APP in brain [16]. For example, there is a burst of increased expression of APP695 during neuronal differentiation. However, following brain injury, expression of the APP751/770 isoforms is substantially increased in astrocytes and microglial cells [17,18]. The reason and functional significance for this apparent tissue-specific alternative splicing is poorly understood.

c) APP Processing

APP is processed in the constitutive secretory pathway and is post-translationally modified by N- and O-glycosylation, phosphorylation and tyrosine sulfation (reviewed in [19]). Full-length APP is sequentially processed by at least three proteases termed α -, β - and γ -secretases (Figure 2). Cleavage by α -secretase or β -secretase within the luminal/extracellular domain results in the shedding of nearly the entire ectodomain to yield large soluble APP derivatives (called APPs α and APPs β , respectively) and generation of membrane-tethered α - or β -carboxyl-terminal fragments (APP-CTF α and APP-CTF β). The APP-CTFs are subsequently cleaved by γ -secretase to generate either a 3 kDa product (p3, from APP-CTF α) or A β (from APP-CTF β), and the APP intracellular domain (AICD).

The major neuronal β -secretase is a transmembrane aspartyl protease, termed BACE1 (β -site APP cleaving enzyme; also called Asp-2 and memapsin-2) [20-24], and cleavage by BACE1 generates the N-terminus of A β . There is an alternative BACE (β') cleavage site following Glu at position +11 of the A β peptide [25]. In addition, there is a BACE2 homolog which is expressed widely but does not appear to play a role in A β generation as it appears to cleave near the α -secretase site [26,27]. Of note, cathepsin B has also been proposed to act as a β -secretase [28,29], but whether generation of A β in brain requires the coordinated action of both BACE1 and cathepsin B is not known but unlikely given the near total loss of A β in BACE1 deficient mice [23,24,30].

While cleavage at the β -site is specific to BACE1 and possibly cathepsin B, it was initially believed that a number of proteases, specifically members of the ADAM (a disintegrin and metalloprotease) family of proteases including ADAM9, ADAM10 and ADAM17



are candidates for the α -secretase (reviewed in [31]). It was reported that APP α -secretase cleavage can be stimulated by a number of molecules, such as phorbol ester or via protein kinase C activation, in which case, this so-called regulated cleavage is mediated by ADAM 17, also called TACE (tumor necrosis factor α -converting enzyme) [32,33]. However, recent studies indicated that constitutive α -secretase activity is likely to be mediated by ADAM10 [34]. Interestingly, ADAM10 is transcriptionally regulated by sirtuins [35], thus providing a mechanism where augmentation of α -secretase activity competes for β -secretase cleavage to lower generation of full length A β peptide. However, it should be noted that cleavage of APP by α -secretase processing only precludes the formation of an intact full length A β peptide. Although this latter event is commonly called the non-amyloidogenic pathway, it is unfortunately a bit of a misnomer because truncated A β (p3 peptide) from 17-42 is also deposited in brains of AD and Down Syndrome patients [36-38], indicating that shorter A β peptides starting at the α -secretase site may contribute to some aspects of AD-associated amyloid pathology [39,40].

As regards to γ -secretase cleavage that releases A β from the membrane, this activity is executed by a high molecular weight complex consisting of presenilin (PS), nicastrin, anterior pharynx defective (APH1) and presenilin enhancer (PEN2) (reviewed in [41,42]). Although these four proteins form the mature γ -secretase complex, it appears that the core γ -secretase activity resides within presenilin itself functioning as an aspartyl protease [43,44]. In addition to generating A β peptides of different lengths, γ -secretase appears to cleave APP in multiple sequential steps [45-47]. An initial cleavage, termed ϵ -cleavage, taking place 3-4 residues from the cytoplasmic membrane face begins this process [48,49]. Elegant studies by Ihara and colleagues [50-53] have led to a model whereby sequential cleavages taking place every three residues along the α -helical face of the transmembrane domain of APP shortens the C-terminus to ultimately result in the release of A β .

It is worth mentioning that none of the secretases have unique substrate specificity towards APP. Besides APP, several transmembrane proteins such as growth factors, cytokines and cell surface receptors and their ligands, undergo ectodomain shedding by enzymes with α -secretase activity (see [54] for an overview). The relatively low affinity of BACE1 toward APP led to the suggestion that APP is not its sole physiological substrate. Indeed, neuregulin-1 (NRG1) now appears to be a bona fide substrate of BACE1 such that the shedding of NRG1 initiated by BACE1 cleavage would direct Schwann cells to myelinate peripheral nerves during development [55,56]. Similarly, γ -secretase has been

reported to cleave more than 50 type I membrane proteins in addition to APP (reviewed by [57]), an event that requires an initial ectodomain shedding event, usually by α -secretase-mediated cleavage. While this cleavage in some cases has been demonstrated to initiate intracellular cell signaling, as exemplified by the γ -secretase dependent Notch activation, whether this also applies to APP and other γ -secretase substrates remains unconfirmed (see below and discussed in [58]).

B. The Full-length APP

a) Cell Surface Receptor

Ever since the cloning of APP cDNA, APP has been proposed to function as a cell surface receptor. Further, the analogy between the secondary structures and proteolytic processing profiles between the Notch receptor and APP also suggests that APP could function as a cell surface receptor similar to Notch (reviewed in [59]). In support of this hypothesis, Yankner and colleagues reported that A β could bind to APP and thus could be a candidate ligand for APP [60], a finding that has been replicated by others [61]. Another piece of evidence came from Ho and Sudhof (2004) who showed that the APP extracellular domain binds to F-spondin, a neuronally secreted glycoprotein, and this interaction regulates A β production and downstream signaling [62]. Similarly, the Nogo-66 receptor has been shown to interact with the APP ectodomain and by which means affect A β production [63]. Another interacting protein recently reported is Netrin-1, a soluble molecule with multiple properties including axonal guidance through chemoattraction and tumorigenesis [64]. In this instance, addition of netrin-1 to neuronal cultures led to reduction in A β levels but also increased APP-Fe65 complex formation, thus suggesting a role in cell signaling (see below). Recently, work from the D'Adamio group showed that BRI2 could function as a putative ligand or co-receptor for APP and modulates APP processing [65,66]. Finally, the fact that the extracellular domains of the APP family of protein could potentially interact in *trans* (discussed below) suggest that APP molecules can interact in a homophilic or heterophilic manner between two cells. Overall, although a number of APP interacting proteins have been identified, it is unclear whether any of the candidates are *bona fide* ligands and definitive evidence supporting a physiological role of APP to function as a cell surface receptor is still lacking.

b) Cell and Synaptic Adhesion

The E1 and E2 regions in the extracellular domain of APP have been shown to interact with extracellular matrix proteins and heparin sulfate proteoglycans (reviewed in [67]), supporting its role in cell-substratum adhesion. The same sequences have also been implicated in cell-cell interactions. Specifically, X-ray analysis

revealed that the E2 domain of APP could form parallel or antiparallel dimers [68], the latter structure would imply that there is a potential to function in trans-cellular adhesion. Indeed, cell culture studies support the homo- or hetero-dimer formation of the APP family members, and trans-dimerization was shown to promote cell-cell adhesion [69]. It was further shown that heparin binding to the E1 or E2 region would induce the formation of APP dimerization [70]. Besides the E1 and E2 regions, recent studies suggest that homodimerization can be promoted by the GxxxG motif near the luminal face of the membrane [71,72]. Interestingly, mutagenesis of the glycine residues in this motif resulted in production of truncated A β peptides of 34, 35, and 38 amino acids in length [71]. On the other hand, it is unclear whether these changes in A β generation are strictly related to APP dimerization because forced dimerization of APP with a bifunctional cross-linking agent did not lead to the same changes in A β profile [73]. In addition, while trans-dimerization would be expected to play a role in cell-cell interactions or adhesion, it is less clear what the cellular consequences of cis-homodimerization of APP are, aside from the alterations in A β peptides noted earlier. One possible role of dimerization is through downstream activity of the AICD peptide that is released after ϵ -cleavage, but support for this idea remains controversial. Interestingly though, using various reporter constructs, the subcellular localization of dimerized APP and APLP2 was reported to be different to that of APLP1 [74], suggesting that there are subtle functional roles in homo- or heterodimerization of the APP gene family that remain to be elucidated. Lastly, near the beginning of the A β sequence (and near the C-terminus of APPs) is a "RHDS" tetra-peptide motif that also appears to promote cell adhesion. It is believed that this region acts in an integrin-like manner by its homology to the "RGD" sequence [75]. In this regard, it is interesting that APP colocalizes with integrins on the surface of axons and at sites of adhesion [76,77]. In support of these earlier observations, it was recently shown that APP and integrin- β 1 do interact [78] and that siRNA mediated silencing of APP during development led to defects in neuronal migration that may be related to cell adhesion [79], potentially to extracellular matrix proteins, with or without participation by integrins.

More compelling evidence of trans-APP dimerization was recently obtained in a primary neuron/HEK293 mixed culture assay. In this culture system, it was reported that trans-cellular APP/APP interaction induces presynaptic specializations in co-cultured neurons [80]. These studies identified APP proteins as a novel class of synaptic adhesion molecules (SAM) with shared biochemical properties as neurexins (NX)/neuroligins (NL), SynCAMs, and leucine-rich repeat transmembrane

neuronal proteins (LRRTM) [81-86]. Like NX/NL and SynCAM-mediated synaptic adhesion in which extracellular sequences engage in trans-synaptic interactions and the intracellular domains recruit pre- or postsynaptic complexes (reviewed in [87]), both the extracellular and intracellular domains of APP are required to mediate the synaptogenic activity. Interestingly, using an affinity tagged APP molecule expressed in transgenic mice, the identified "APP-interactome" consisted of many proteins, such as Bassoon and neurexin, that are synaptic in localization [88]. Whether APP trans-synaptic interaction is involved in the recruitment of these synaptic molecules and whether APP coordinates with other synaptic adhesion complexes such as neurexin are interesting questions that warrant further investigation.

C. The APP Ectodomain

Various subdomains can be assigned to the APP extracellular sequences based on its primary sequences and structural studies (Figure 1) (reviewed in [89,90]). These include the E1 domain, which consists of the N-terminal growth factor-like domain (GFLD) and the metal (copper and zinc) binding motif, the KPI domain present in APP751 and APP770 isoforms, and the E2 domain which includes the RERMS sequence and the extracellular matrix components. We address below the functional studies associated with the APP extracellular domain.

a) *Synaptotrophic and Neuroprotective Functions*

A number of publications have pointed to a neurotrophic role of the APP extracellular domain in both physiological and pathological settings, and this function may be linked to its adhesive properties described above either in its full-length form or as a secreted molecule (i.e. APPs) following ectodomain shredding. Thus, APP may exert these activities in both autocrine and paracrine fashions. Of note, APP undergoes rapid anterograde transport and is targeted to the synaptic sites [16,91-93], where levels of secreted APP coincide with synaptogenesis [94]. APP expression is upregulated during neuronal maturation and differentiation [95,96]. Its expression is also induced during traumatic brain injury both in the mammalian system and in *Drosophila* [18,97-99].

The crystal structure of the E1 domain shows similarities to known cysteine-rich growth factors and thus this domain in the N-terminus of APP has been linked to growth factor-like domain (GFLD) that is seen in the epidermal growth factor receptor [100]. One of the earliest indications of APP function came from the observation that assessing fibroblasts treated with an antisense *APP* construct grew slower and the growth retardation can be restored by treatment with secreted APPs [101]. The active domain was subsequently mapped to a pentapeptide domain "RERMS" in the E2

domain [102]. The activity is not limited to fibroblasts as infusion of this pentapeptide or APPs α into the brain resulted in increased synaptic density and better memory retention, while injection of APP antibodies directly into the brain led to impairment in behavioral tasks in adult rat [103]. Application of APPs α resulted in reduced neuronal apoptosis and improved functional recovery following traumatic brain injury (TBI) [103-105]; it also antagonized dendritic degeneration and neuronal death triggered by proteasomal stress [106]. These findings are corroborated by additional reports showing that reduction or loss of APP is associated with impaired neurite outgrowth and neuronal viability *in vitro* and synaptic activity *in vivo* [107-109]. Recent studies have further substantiated these early findings, showing for example that APPs regulates NMDA receptor function, synaptic plasticity and spatial memory [110], and that the growth promoting property may be mediated by the down-regulation of CDK5 and inhibition of tau hyperphosphorylation by APPs α [111]. Finally, a number of studies have reported the effects of APPs α on stem cells. Caille et al. first demonstrated the presence of binding sites for APPs in epidermal growth factor (EGF)-responsive neural stem cells in the subventricular zone in the adult rodent brain [112]. In this context, APPs α acts as a co-factor with EGF to stimulate the proliferation of these cells both in neurospheres in culture and *in vivo*. Subsequently, it was reported that APPs promoted neurite outgrowth in neural stem cells where APLP2 but not APLP1 was redundant to APP [113]. However and intriguingly, stem cells from APP/APLP1/APLP2 triple knockout embryos did not show any defects in neuronal differentiation *in vitro* [114]. Furthermore, in APP transgenic mice, overexpression of wild type APP resulted in decreased neurogenesis but promoted survival of newly generated cells [115]. At the moment, it is unclear how all these findings can be reconciled in a parsimonious picture of APP trophic functions.

Li et al. recently uncovered a novel role for APPs to regulate gene expression likely through binding to an unknown receptor [116]. In particular, they identified transthyretin (TTR) and Klotho as downstream targets of APP that are mediated by APPs β . These targets are of direct relevance to AD as TTR has been shown to bind and sequester A β [117-119], and Klotho has been extensively implicated in the aging process [120-122]. The regulation of TTR and Klotho expression by APPs β offers the intriguing possibility for a self-protective mechanism in the APP processing pathway to counter the production and toxicity of A β during aging. Because APPs levels have been reported to be reduced in individuals with AD [123-126], the results support the view that the loss of trophic activity or the defence

mechanism of APPs may contribute at least in part to the neurodegeneration in AD.

Lastly and perhaps related to the growth promoting property of APP, an area that has come to light concerning APP function involves carcinogenesis, coinciding with the recent observation of an inverse association between cancer and AD [127]. Previous studies have reported an up-regulation of APP in various solid tumors. The reason for this is unclear but a recent study demonstrated that APP plays a role in growth of cancer cells [128]. Whether this potential tumorigenic activity involves adhesion, trophic properties of APPs, or cell signaling remain to be established.

b) Axonal Pruning and Degeneration

Whereas ample evidence support a role of APPs α in synaptotrophic and neuroprotective activities, APPs β is known to be much less active or even toxic (reviewed in [129]). The differential activities between APPs α and APPs β are difficult to comprehend considering that there are only 17 amino acid differences between the two isoforms and sequences implicated in trophic activities are mapped outside this region and common to both isoforms. The most striking finding related to differences between APPs α and APPs β came from Nikolaev et al. who reported that, under trophic withdrawal conditions, APPs β but not APPs α undergoes further cleavage to produce an N-terminal ~35 kDa derivative (N-APP), which binds to DR6 death receptor and mediates axon pruning and degeneration [130]. The authors attempted to link this pathway to both axonal pruning during normal neurodevelopment and neurodegeneration occurring in AD. However, by using recombinant APPs β *in vitro* and by creating APPs β knockin mice *in vivo* [116], Li et al. demonstrate that APPs β is highly stable and that APPs β fails to correct the nerve sprouting phenotype of the *APP/APLP2* null neuromuscular synapses (discussed in detail under "APP knockin mice"). Therefore, the biological and pathogenic relevance of the APPs β /DR6 pathway outside of the trophic withdrawal paradigm requires further examination.

D. The APP Intracellular Domain

The high degree of sequence conservation between the intracellular domains of APP proteins predicts that it is a critical domain mediating APP function. Indeed, this relatively short cytoplasmic domain of 47 amino acid residues contains one well described phosphorylation site as well as multiple functional motifs and multiple binding partners that contribute to trafficking, metabolism, and possibly cell signaling functions of APP.

a) Phosphorylation and Protein-Protein Interaction

APP can be phosphorylated at multiple sites in both extracellular and intracellular domains (reviewed by

[131]). Among these, the phosphorylation at the threonine residue within the VT⁶⁶⁸PEER motif (Thr⁶⁶⁸) in the APP intracellular domain (Figure 1) has received most of the attention. Several kinases have been implicated in this phosphorylation event, including cyclin-dependent kinase 5 (CDK5), c-Jun N-terminal kinase 1 (JNK1) and JNK3, CDK1/CDC2 kinase and GSK3 β [132-135]. Phosphorylation at this residue has been reported to result in several outcomes. First, it has been implicated to regulate APP localization to the growth cones and neurites [134,136], a finding consistent with the preferential transport of Thr⁶⁶⁸ phosphorylated APP to nerve terminals [137]. Second, phosphorylation at Thr⁶⁶⁸ has been reported to contribute to A β generation, a finding consistent with an increase of Thr⁶⁶⁸ phosphorylated APP fragments in brains of AD individuals [138]. Third, Thr⁶⁶⁸ phosphorylation leads to resistance of APP to be cleaved by caspases between Asp⁶⁶⁴ and Ala⁶⁶⁵ residues, an event that has been proposed to result in increased vulnerability to neuronal death (see below). Fourth, phosphorylation at Thr⁶⁶⁸ leads to a conformational change in the APP cytoplasmic domain such that interaction with the cytoplasmic adaptor Fe65 through the distal YENPTY motif [139] is altered, thereby affecting the proposed nuclear signaling activity of the APP-Fe65 complex [140]. As the YENPTY motif has been shown to bind several other cytosolic adaptor proteins, it is not surprising then that Thr⁶⁶⁸ phosphorylation has also been reported to modulate APP interaction with Mint-1/X11a [141]. Lastly, following phosphorylation, it has been shown that the peptidyl-propyl cis/trans isomerase Pin1 catalyzes the cis to trans isomerization of the Thr⁶⁶⁸-Pro⁶⁶⁹ bond and this is predicted to alter APP conformation [142], possibly related to the Fe65 or Mint-1/X11a interaction with APP. In support of this idea, it was shown that loss of Pin1 in mice resulted in accumulation of hyperphosphorylated tau and increased A β levels [142,143], two features that should accelerate AD pathology in the brain. Nevertheless, knockin mice replacing the Thr668 with a non-phosphorylatable Ala residue did not result in substantive changes in either APP localization or in the levels of A β in brain [144], raising the question whether Thr⁶⁶⁸ phosphorylation plays a significant role in regulating APP trafficking and A β generation *in vivo*.

In addition to Thr⁶⁶⁸ phosphorylation, the highly conserved APP intracellular domain has been shown to bind to numerous proteins (reviewed in [145,146]). Of particular interest and relevance to this review, the Y⁶⁸²ENPTY motif is required to interact with various adaptor proteins, including Mint-1/X11a (and the family members Mint-2 and Mint-3, so named for their ability to interact with Munc18), Fe65 (as well as Fe65 like proteins Fe65L1 and Fe65L2) and c-Jun N-terminal kinase

(JNK)-interacting protein (JIP), through the phosphotyrosine-binding (PTB) domain. The Y⁶⁸² has been shown to modulate APP processing *in vivo* [147]. Of interest is the finding that Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and amyloidogenic processing [148].

b) Apoptosis

In contrast to the trophic activities of the soluble APP ectodomain, there are also a number of papers demonstrating the cytotoxic properties of β -secretase cleaved APP CTF (or C99), especially following overexpression [149-151]. The mechanism by which APP CTF is cytotoxic is unclear but one pathway may be through AICD released from APP CTF following ϵ -cleavage. Normally, AICD exists in very low levels *in vivo* but can be stabilized when Fe65 is overexpressed [152-154]. In cultured cells, overexpression of AICD led to cell death [154-156]. In transgenic mice overexpressing an AICD construct, there was activation of GSK-3 β but no overt neuronal death [157,158], findings not replicated in a subsequent study however [159]. Interestingly, in mice expressing both AICD and Fe65, neuronal degeneration was observed in old mice together with tau hyperphosphorylation. Furthermore, behavioral abnormalities seen in these animals can be rescued by treatment with lithium, a GSK-3 β inhibitor, in line with earlier evidence of activation of GSK-3 β [160].

Another aspect of APP CTF mediated cytotoxicity concerns a caspase cleavage site within the cytosolic tail between position Asp⁶⁶⁴ and Ala⁶⁶⁵ [161]. In cell culture systems, loss of this caspase site by mutating the Asp⁶⁶⁴ to Ala (D664A) resulted in an attenuation of APP C99 associated cytotoxicity. It has been proposed that release of the smaller fragments (C31 and Jcasp) from AICD after cleavage at position 664 results in the generation of new cytotoxic APP related peptides [162]. Thus, overexpression of either C31 or Jcasp, both derived from AICD, have resulted in cytotoxicity. Consistent with these *in vitro* findings, in an APP transgenic mouse line in which the caspase site is mutated to render APP non-cleavable, the predicted A β -related phenotypes in brain (synaptic, behavior, and electrophysiological abnormalities) were absent in spite of abundant amyloid deposits [163,164]. Therefore, these initial observations indicated that the release of the smaller fragments (C31 or Jcasp) after caspase cleavage of C99 may result in cell death in a manner independent of γ -secretase [165]. However, analysis of another line of APP D664A transgenic mice with substantially higher APP expression failed to replicate the earlier findings [166], but the wide differences in expression of the transgene and resultant A β levels between the two transgenic mouse lines is such that the

comparisons may be invalid [167]. In sum, there are at present several potential mechanisms whereby APP may contribute to neurotoxicity: via γ -secretase cleavage to release AICD or via alternative cleavage of the APP C-terminus to release other cytotoxic peptides. Whether these APP fragments contribute to *in vivo* neuronal death in AD pathogenesis remain to be established.

c) Cell Signaling

As mentioned previously, in addition to γ -secretase cleavage that yields A β 40 and A β 42, presenilin-dependent proteolysis appears to begin at the ϵ -site (A β 49) close to the membrane-intracellular boundary [46,48,49]. Thus the ϵ -cleavage of APP may represent the primary or initial presenilin-dependent processing event. This is important because this cleavage releases AICD in a manner highly reminiscent of the release of the Notch intracellular domain (NICD) after γ -secretase processing, the latter being an obligatory step in Notch mediated signaling (reviewed in [59]). The predominant ϵ -cleavage releases AICD of 50 amino acids in length (CTF50-99), beginning with a Val residue. APP mutations that shift A β production in favor of A β 42 would lengthen the AICD by one amino acid (CTF 49-99), now beginning with a Leu residue. This is of some interest because it has been pointed out that the N-end rule guiding protein stability through ubiquitination states that Val is a stabilizing residue while Leu is destabilizing (Reviewed in [168]). NICD, the intracellular domain derived from the Notch receptor, appears to follow this principle experimentally. If this situation applies to AICD, then there could be a different regulatory mechanism at play regarding AICD mediated cell signaling or in cell death. Furthermore, recent studies have suggested that AICD generation is in part dependent on whether APP was previously cleaved by α - or β -secretase, indicating yet another layer of regulation [169,170]. Nonetheless, AICD is indeed very labile and, as mentioned previously, can be stabilized by Fe65 [153], a finding seen both in the *in vitro* and *in vivo* settings. A good deal of excitement followed the first report in which by using a heterologous reporter system, AICD was shown to form a transcriptionally active complex together with Fe65 and Tip60 [157,171]. This finding appeared to validate the notion that AICD is transcriptionally active, much like NICD. Scheinfeld et al. proposed a JIP-1 dependent transcriptional activity of AICD [172]. However, subsequent analyses have suggested that the earlier view may be too simplistic and incomplete. First, follow up studies by Cao et al. showed that AICD facilitates the recruitment of Fe65 but its nuclear translocation *per se* is not required [173]. Second, PS-dependent AICD production is not a prerequisite for the APP signaling activity, as it proceeds normally in PS null cells and by PS inhibitor treatment [174]. Instead, the authors provide an

alternative pathway for this activity that involves Tip60 phosphorylation. Third, a later report documented that the proposed signaling activity is actually executed by Fe65 and that APP is not required altogether [175]. Lastly, Giliberto et al. reported that mice transgenic for AICD in neuronal cells are more susceptible to apoptosis. However, analysis of the basal transcription showed little changes in mice expressing AICD in the absence of Fe65 overexpression, leaving open the possibility that transcription may be influenced in a regulated fashion [176].

Regardless of the mechanism by which AICD may activate signaling pathways, a trans-activating role of the APP/Fe65/Tip60 complex has been consistently documented, at least in overexpression systems. However, these efforts have led to decidedly mixed results. A number of genes have been proposed to date including KAI [177], GSK3 β [158,178], neprilysin [179], EGFR [180], p53 [181], LRP [182], APP itself [183], and genes involved in calcium regulation [184] and cytoskeletal dynamics [185]. However, the validity of these proposed targets have been either questioned or disputed [175,176,186-190]. Thus, at present, a conservative view is that these target genes are indirectly or only weakly influenced by AICD mediated transcriptional regulation.

E. *In vivo* Function of APP

The *in vivo* gain- and loss-of-function phenotypes associated with the APP family of proteins in model systems (*C. elegans*, *Drosophila* and mice) are consistent with a role of APP in neuronal and synaptic function in both central and peripheral nervous systems. This may be mediated by the APP ectodomain or requires the APP intracellular domain. These findings will be discussed next in the respective animal models.

a) *C. elegans*

The *C. elegans* homolog of APP, APL-1, resembles the neuronal isoform APP695 as there are no known splice variants detected. Similar to APLP1 and APLP2, APL-1 does not contain the A β sequence. Nematode development includes four larval stages (L1-L4) after each of which is a molt where a new, larger exoskeleton is formed to accommodate the growth of the larvae. Inactivation of the single *apl-1* gene leads to developmental arrest and lethality at the L1 stage, likely due to a molting defect [191,192]. In addition, *apl-1* knockdown leads to hypersensitivity to the acetylcholinesterase inhibitor aldicarb, signifying a defect in neurotransmission [192]. The aldicarb hypersensitivity phenotype and the molting defect were found to be independent of one another, suggesting *apl-1* contributes to multiple functions within the worm. Surprisingly, both phenotypes were rescued by either a membrane-anchored C-terminal truncation of APL-1 or by the soluble N-terminal

fragments, showing that the highly conserved C-terminus is not required to support the viability of the worm [191,192]. This differs from the mammalian system in which the APP C-terminus is essential for viability on a non-redundant background (see discussion under "APP knock-in mice") [116,193]. Although the reason for the distinct domain requirement for *C. elegans* and mouse viability is not clear, it is worth reiterating that the lethality of the *apl-1* null worm is likely caused by a molting defect not relevant to mammals. Consistent with this interpretation, it is interesting that expression of mammalian APP or its homologs are not able to rescue the *apl-1* null lethality [191,192], indicating that this worm-specific molting activity is lost during mammalian evolution and that extrapolation of APP function from *apl-1* may not be very informative.

b) Drosophila

The *Drosophila* APP homolog, APPL, like the worm homolog, does not contain the A β sequence and does not undergo alternative splicing. However, in contrast to the *apl-1* null worm, *Appl*-deficient flies are viable with only subtle behavioral defects such as fast phototaxis impairment [3]. While human APP is not able to rescue the *C. elegans apl-1* lethality, the behavioral phenotype present in the *Appl* null fly can be partially rescued by transgenic expression of either fly APPL or human APP [3]. Subsequent loss and gain-of-function studies revealed that APPL plays an important role in axonal transport, since either *Appl* deletion or overexpression caused axonal trafficking defects similar to kinesin and dynein mutants [194,195]. Although a similar role for APP in axonal transport of selected cargos has been reported [196-198], the findings have since been challenged by several laboratories [199].

APPL is required for the development of neuromuscular junctions (NMJs), since *Appl* deletion leads to decreased bouton number of NMJs, whereas *Appl* overexpression dramatically increases the satellite bouton number [200]. This activity can be explained by the formation of a potential complex including APPL, the APPL-binding protein dX11/Mint, and the cell adhesion molecule FasII, which together regulate synapse formation [201]. Overexpression of human APP homologs in *Drosophila* revealed a spectrum of other phenotypes, ranging from 1) a blistered wing phenotype that may involve cell adhesion [202], 2) a Notch gain-of-function phenotype in mechano-sensory organs, which reveals a possible genetic interaction of APP and Notch through Numb [203], and 3) a neurite outgrowth phenotype that is linked to the Abelson tyrosine kinase and JNK stress kinase [99]. Although the pathways implicated in each of the phenotypes are distinct, they all seem to require the APP intracellular domain via protein-protein interactions mediated through the conserved YENPTY

sequence. These ectopic overexpression studies should be interpreted with caution because APP interacts with numerous adaptor proteins and many of the APP binding partners also interact with other proteins. Therefore, the phenotypes observed by overexpressing APP or APPL could be caused by the disturbance of a global protein-protein interaction network.

Interestingly, similar to the mammalian system, APPL is found to be upregulated in traumatic brain injury and *Appl*-deficient flies suffer a higher mortality rate compared to controls [99], supporting an important activity of APP family of proteins in nerve injury response and repair.

c) Mice

i. APP single knockout mice Three mouse *APP* alleles, one carrying a hypomorphic mutation and two with complete deficiencies of *APP* have been generated [204-206]. The *APP* null mice are viable and fertile but exhibit reduced body weight and brain weight. Loss of APP results in a wide spectrum of central and peripheral neuronal phenotypes including reduced locomotor activity [204,205,207], reactive gliosis [205], strain-dependent agenesis of the corpus callosum [205,208], and hypersensitivity to kainate induced seizures [209]. Although these phenotypes indicate a functional role of APP in the CNS, the molecular mechanisms mediating these effects remain to be established. Unbiased stereology analysis failed to reveal any loss of neurons or synapses in the hippocampus of aged *APP* null mice [210]. Attempts to examine spine density in *APP* KO mice have yielded mixed results. Using hippocampal autaptic cultures, Priller et al. reported an enhanced excitatory synaptic response in the absence of *APP*, and the authors attributed this effect to the lack of A β production [211]. Follow up studies by the same group reported that *APP* deletion led to a two-fold higher dendritic spine density in layers III and V of the somatosensory cortex of 4-6 month-old mice [212]. However, Lee et al. found a significant reduction in spine density in cortical layer II/III and hippocampal CA1 pyramidal neurons of one-year old *APP* KO mice compared with WT controls [213]. It is not clear whether differences in age or brain region may contribute to the discrepancy.

The *APP* null mice show impaired performances in Morris water maze and passive avoidance tasks, and the behavioral deficits are associated with a defect in long term potentiation (LTP) [207,210,214,215], the latter may be attributed to an abnormal GABAergic paired pulse depression [215]. Follow up work demonstrated that APP modulates GABAergic synaptic strength by regulating Cav1.2 L-type calcium channel (LTCC) expression and function in striatal and hippocampal GABAergic neurons [216]. APP deficiency leads to an increase in the levels of α 1C, the pore forming subunit

of Cav1.2 LTCCs and an enhanced Ca^{2+} current, which in turn results in reduced GABAergic mediated paired-pulse inhibition and increased GABAergic post-tetanic potentiation [216]. A role of APP in calcium regulation is further documented by APP overexpression and knockdown studies in hippocampal neurons which support an $A\beta$ independent role of APP in the regulation of calcium oscillations [217].

Outside of the CNS, *APP* deficient mice display reduced grip strength [205,207]. This is likely due to impaired Ca^{2+} handling at the neuromuscular junction (NMJ) as functional recordings revealed that *APP* null mice show abnormal paired pulse response and enhanced asynchronous release at NMJ resulting from aberrant activation of voltage gated N- and L-type calcium channels at motor neuron terminals [218]. Taken together, the studies thus provide strong support for the notion that APP plays an important role in Ca^{2+} homeostasis and calcium-mediated synaptic responses in a variety of neurons, including GABAergic and cholinergic neurons and possibly others, through which it may regulate the neuronal network and cognitive function.

ii. *APP*, *APLP1*, *APLP2* compound knockout mice The relatively subtle phenotypes of *APP* deficient mice are likely due to genetic redundancies as evidenced by gene knockout studies. While mice with individual deletion of *APP*, *APLP1* and *APLP2* are viable, *APP/APLP2* and *APLP1/APLP2* double knockout mice or mice deficient in all three APP family members are lethal in the early postnatal period [219,220]. Intriguingly and due to reasons not well understood, the *APP/APLP1* double null mice are viable [220]. Although the NMJ of *APP* or *APLP2* single null mice do not show overt structural abnormalities, the *APP/APLP2* double knockout animals exhibit poorly formed neuromuscular synapses with reduced apposition of presynaptic proteins with postsynaptic acetylcholine receptors and excessive nerve terminal sprouting [221]. The number of synaptic vesicles at the presynaptic terminals is reduced, a finding consistent with defective neurotransmitter release. Examination of the parasympathetic submandibular ganglia of the double deficient animals also showed a reduction in active zone size, synaptic vesicle density, and number of docked vesicles per active zone [222].

Interestingly, tissue-specific deletion of *APP* either in neurons or in muscle on *APLP2* knockout background resulted in neuromuscular defects similar to those seen in global *APP/APLP2* double null mice, demonstrating that APP is required in both motoneurons and muscle cells for proper formation and function of neuromuscular synapses [80]. The authors propose that this is mediated by a trans-synaptic interaction of APP, a model that gained support by hippocampal and HEK293 mixed culture assays described above [80]. Interestingly, muscle

APP expression is required for proper presynaptic localization of CHT and synaptic transmission, suggesting that trans-synaptic APP interaction is necessary in recruiting presynaptic APP/CHT complex [80,223].

Analysis of *APP/APLP1/APLP2* triple knockout mice revealed that the majority of the animals showed cortical dysplasia suggestive of neuronal migration abnormalities and partial loss of cortical Cajal Retzius cells [224]. Interestingly, this defect is phenocopied in mice doubly deficient in APP binding proteins Fe65 and Fe65L1 [225]. It should be pointed out however, that morphological similarity does not necessarily implicate functional interaction. Indeed, cortical dysplasia with viable penetrance also exists in mice deficient in various other proteins including PS1, $\beta 1$ and $\alpha 6$ integrins, focal adhesion kinase, α -dystroglycan and laminin $\alpha 2$ (reviewed in [226]).

In sum, the loss-of-function studies present a convincing picture that members of the *APP* gene family play essential roles in the development of the peripheral and central nervous systems relating to synapse structure and function, as well as in neuronal migration or adhesion. These may be mediated either by the full-length protein or by various proteolytic processing products, and may be due to mechanical properties or through activating signaling pathways, or both. The creation of knockin alleles expressing defined proteolytic fragments of APP offers a powerful system to delineate the APP functional domains *in vivo*. These are discussed in the following section.

iii. *APP* Knock-in mice To date, four *APP* domain knock-in alleles have been reported and these express α -secretase (*APPs α* [227]) or β -secretase (*APPs β* [116]) processed soluble APP, the membrane anchored protein with deletions of either the last 15 aa (*APP Δ CT15* [227]) or 39 aa (*APP/hA β /mutC* [193]) of the highly conserved C-terminal sequences of APP, the latter also replaced mouse $A\beta$ with the human sequence and introduced three FAD mutations (Swedish, Arctic, and London) to facilitate $A\beta$ production. The *APPs α* and *APP Δ CT15* knock-in mice appeared to rescue a variety of phenotypes observed in *APP* KO mice [227]. For instance, the reduced body and brain weight of *APP* null animals was largely rescued. Behaviorally, the knock-in mice do not exhibit any defects in grip strength or the Morris water maze test. Field recordings of hippocampal slices showed that the LTP deficits observed in 9-12 month-old *APP* KO mice was also absent in both knock-in lines. These findings are in agreement with the large body of literature documenting the synaptotrophic activity of *APPs α* (refer to "Synaptotrophic and Neuroprotective Functions" above) and that perhaps the predominant function of APP is mediated by *APPs α* .

Similar to *APPs α* and *APP Δ CT15* knock-in lines, the *APPs β* and *APP/hA β /mutC* mice did not show any overt

growth or anatomical deficits. However and in stark contrast to the aforementioned two knockin mouse lines, crossing these two alleles (APPs β or anchored APP/hA β /mutC) to *APLP2*^{-/-} background failed to rescue the early postnatal lethality and neuromuscular synapse defects of the *APP/APLP2* KO mice [116,193], suggesting a critical and indispensable role of the conserved C-terminal region of APP in early postnatal development. An essential role of the APP C-terminal domain, specifically the YENPTY motif, in development was demonstrated by the creation of APP knock-in mice in which the Tyr⁶⁸² residue of the Y⁶⁸²ENPTY sequence was changed to Gly (APP^{YG}). Crossing the homozygous knock-in mice to *APLP2* null background showed that the *APP*^{YG/YG}/*APLP2*^{-/-} mice exhibit neuromuscular synapse deficits and early lethality similar to *APP/APLP2* double KO mice [228]. The differences in outcomes in these experiments are difficult to explain but may be related to a more severe phenotype in the *APLP2* deficient background. Nevertheless, the inability to rescue the NMJ defects by the APP mutants lacking the intracellular domain or expressing the Tyr⁶⁸² to Gly mutation is compatible with the concept that APP functions as a synaptic adhesion protein. Furthermore, the fact that amyloid deposition can develop in the absence of the APP C-terminal sequences indicates that APP developmental function and amyloidogenesis are differentially regulated and require distinct APP domains [193].

Concluding Remarks

We hope this review has provided a timely update on what is known and what lies ahead in the field of APP biology. Since the first identification of the APP gene in 1987, the scientific community has worked together to obtain significant insights into the biochemical, cellular and functional properties of APP. It is clear that APP undergoes tightly regulated trafficking and processing and, through either the full-length protein and/or its cleavage products, it mediates synaptogenic and synaptotrophic activities in development and during aging. As such, it is reasonable to speculate that misregulation of APP could contribute to the neuronal and synaptic impairment occurring in AD. Many key questions remain to be addressed. These include determining whether APP is a receptor or a ligand and, accordingly, the identities of its respective ligand or receptor. Does APP directly mediate cell signaling or only play a secondary role in gene expression? How is APP function coordinated between its full-length form and the various processing products, and how is it facilitated through its binding partners? Elucidating these questions will undoubtedly reveal novel insights into disease pathogenesis.

Acknowledgements

The authors' work cited in this review was supported by grants from NIH (AG032051 and AG033467 to HZ AG020206 and AG032179 to EHK), and the American Health and Assistance Foundation (to HZ).

Author details

¹Huffington Center on Aging and Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. ²Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.

Authors' contributions

HZ and EHK wrote the manuscript. HZ made the figures. Both authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 13 February 2011 Accepted: 28 April 2011

Published: 28 April 2011

References

1. Daigle I, Li C: *apl-1*, a *Caenorhabditis elegans* gene encoding a protein related to the human beta-amyloid protein precursor. *Proc Natl Acad Sci USA* 1993, **90**(24):12045-9.
2. Rosen DR, et al: A *Drosophila* gene encoding a protein resembling the human beta-amyloid protein precursor. *Proc Natl Acad Sci USA* 1989, **86**(7):2478-82.
3. Luo L, Tully T, White K: Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for *Appl* gene. *Neuron* 1992, **9**(4):595-605.
4. Musa A, Lehrach H, Russo VA: Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. *Dev Genes Evol* 2001, **211**(11):563-7.
5. Okado H, Okamoto H: A *Xenopus* homologue of the human beta-amyloid precursor protein: developmental regulation of its gene expression. *Biochem Biophys Res Commun* 1992, **189**(3):1561-8.
6. van den Hurk WH, Bloemen M, Martens GJ: Expression of the gene encoding the beta-amyloid precursor protein APP in *Xenopus laevis*. *Brain Res Mol Brain Res* 2001, **97**(1):13-20.
7. Goldgaber D, et al: Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. *Science* 1987, **235**(4791):877-80.
8. Tanzi RE, et al: Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science* 1987, **235**(4791):880-4.
9. Wasco W, et al: Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. *Proc Natl Acad Sci USA* 1992, **89**(22):10758-62.
10. Wasco W, et al: Isolation and characterization of *APLP2* encoding a homologue of the Alzheimer's associated amyloid beta protein precursor. *Nat Genet* 1993, **5**(1):95-100.
11. Slunt HH, et al: Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP). *J Biol Chem* 1994, **269**(4):2637-44.
12. Collin RW, et al: Identification and expression of the first nonmammalian amyloid-beta precursor-like protein *APLP2* in the amphibian *Xenopus laevis*. *Eur J Biochem* 2004, **271**(10):1906-12.
13. Martin-Morris LE, White K: The *Drosophila* transcript encoded by the beta-amyloid protein precursor-like gene is restricted to the nervous system. *Development* 1990, **110**(1):185-95.
14. Yoshikai S, et al: Genomic organization of the human amyloid beta-protein precursor gene [published erratum appears in *Gene* 1991 Jun 30;102(2):291-2]. *Gene* 1990, **87**(2):257-63.
15. Lamb BT, et al: Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected] [published erratum appears in *Nat Genet* 1993 Nov;5(3):312]. *Nat Genet* 1993, **5**(1):22-30.
16. Sisodia SS, et al: Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. *J Neurosci* 1993, **13**(7):3136-42.

17. Siman R, et al: Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage. *Neuron* 1989, **3**(3):275-85.
18. Van Den Heuvel C, et al: Upregulation of amyloid precursor protein and its mRNA in an experimental model of paediatric head injury. *J Clin Neurosci* 2000, **7**(2):140-5.
19. De Strooper B, Annaert W: Proteolytic processing and cell biological functions of the amyloid precursor protein [In Process Citation]. *J Cell Sci* 2000, **113**(Pt 11):1857-70.
20. Vassar R, et al: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 1999, **286**(5440):735-41.
21. Yan R, et al: Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity [see comments]. *Nature* 1999, **402**(6761):533-7.
22. Sinha S, et al: Purification and cloning of amyloid precursor protein beta-secretase from human brain [see comments]. *Nature* 1999, **402**(6761):537-40.
23. Cai H, et al: BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. *Nat Neurosci* 2001, **4**(3):233-4.
24. Luo Y, et al: Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. *Nat Neurosci* 2001, **4**(3):231-2.
25. Huse JT, et al: Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. *J Biol Chem* 2002, **277**(18):16278-84.
26. Solans A, Estivill X, de La Luna S: A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase. *Cytogenet Cell Genet* 2000, **89**(3-4):177-84.
27. Yan R, et al: BACE2 functions as an alternative alpha-secretase in cells. *J Biol Chem* 2001, **276**(36):34019-27.
28. Hook V, et al: Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. *Biol Chem* 2005, **386**(9):931-40.
29. Hook VY, Kindy M, Hook G: Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. *J Biol Chem* 2008, **283**(12):7745-53.
30. Roberds SL, et al: BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. *Hum Mol Genet* 2001, **10**(12):1317-24.
31. Lichtenthaler SF: Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. *J Neurochem* 116(1):10-21.
32. Buxbaum JD, et al: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. *J Biol Chem* 1998, **273**(43):27765-7.
33. Blacker M, et al: Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons. *J Neurochem* 2002, **83**(6):1349-57.
34. Kuhn PH, et al: ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *EMBO J* 29(17):3020-32.
35. Donmez G, et al: SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. *Cell* 142(2):320-32.
36. Gowing E, et al: Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. *J Biol Chem* 1994, **269**(15):10987-90.
37. Lalowski M, et al: The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. *J Biol Chem* 1996, **271**(52):33623-31.
38. Tekirian TL, et al: N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. *J Neuropathol Exp Neurol* 1998, **57**(1):76-94.
39. Wei W, et al: Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. *Brain* 2002, **125**(Pt 9):2036-43.
40. Szczepanik AM, Rampe D, Ringheim GE: Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. *J Neurochem* 2001, **77**(1):304-17.
41. Edbauer D, et al: Reconstitution of gamma-secretase activity. *Nat Cell Biol* 2003, **5**(5):486-8.
42. Iwatsubo T: The gamma-secretase complex: machinery for intramembrane proteolysis. *Curr Opin Neurobiol* 2004, **14**(3):379-83.
43. Wolfe MS, et al: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity [In Process Citation]. *Nature* 1999, **398**(6727):513-7.
44. Ahn K, et al: Activation and intrinsic (gamma)-secretase activity of presenilin 1. *Proc Natl Acad Sci USA* 2010, **107**(50):21435-40.
45. Zhao G, et al: Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. *J Biol Chem* 2004, **279**(49):50647-50.
46. Zhao G, et al: (gamma)-Cleavage Is Dependent on (zeta)-Cleavage during the Proteolytic Processing of Amyloid Precursor Protein within Its Transmembrane Domain. *J Biol Chem* 2005, **280**(45):37689-97, Epub 2005 Sep 12.
47. Sato T, et al: Blocking the cleavage at midportion between gamma- and epsilon-sites remarkably suppresses the generation of amyloid beta-protein. *FEBS Lett* 2005, **579**(13):2907-12.
48. Sastre M, et al: Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. *EMBO Rep* 2001, **2**(9):835-41.
49. Weidemann A, et al: A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. *Biochemistry* 2002, **41**(8):2825-35.
50. Qi-Takahara Y, et al: Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. *J Neurosci* 2005, **25**(2):436-45.
51. Yagishita S, et al: Abeta46 is processed to Abeta40 and Abeta43, but not to Abeta42, in the low density membrane domains. *J Biol Chem* 2008, **283**(2):733-8.
52. Yagishita S, et al: DAPT-Induced Intracellular Accumulations of Longer Amyloid beta-Proteins: Further Implications for the Mechanism of Intramembrane Cleavage by gamma-Secretase. *Biochemistry* 2006, **45**(12):3952-60.
53. Takami M, et al: gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. *J Neurosci* 2009, **29**(41):13042-52.
54. Annaert WG, Saftig P: Regulated intramembrane proteolysis—a story about sheddases and I-CliPs. *Semin Cell Dev Biol* 2009, **20**(2):125.
55. Hu X, et al: Bace1 modulates myelination in the central and peripheral nervous system. *Nat Neurosci* 2006, **9**(12):1520-5, Epub 2006 Nov 12.
56. Willem M, et al: Control of peripheral nerve myelination by the beta-secretase BACE1. *Science* 2006, **314**(5799):664-6, Epub 2006 Sep 21.
57. Wolfe MS, Kopan R: Intramembrane proteolysis: theme and variations. *Science* 2004, **305**(5687):1119-23.
58. Kopan R, Ilagan MX: Gamma-secretase: proteasome of the membrane? *Nat Rev Mol Cell Biol* 2004, **5**(6):499-504.
59. Selkoe D, Kopan R: Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci* 2003, **26**:565-97.
60. Lorenzo A, et al: Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. *Nat Neurosci* 2000, **3**(5):460-4.
61. Lu DC, et al: Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. *Ann Neurol* 2003, **54**(6):781-9.
62. Ho A, Sudhof TC: Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. *Proc Natl Acad Sci USA* 2004, **101**(8):2548-53.
63. Park JH, et al: Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. *J Neurosci* 2006, **26**(5):1386-95.
64. Lourenco FC, et al: Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production. *Cell Death & Differentiation* 2009, **16**(5):655-63.
65. Matsuda S, et al: Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. *Neurobiol Aging* 2009.
66. Gillberto L, et al: Generation and initial characterization of FDD knock in mice. *PLoS One* 2009, **4**(11):e7900.
67. Small DH, et al: Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. *J Alzheimers Dis* 1999, **1**(4-5):275-85.

68. Wang Y, Ha Y: The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. *Mol Cell* 2004, **15**(3):343-53.
69. Soba P, et al: Homo- and heterodimerization of APP family members promotes intercellular adhesion. *Embo J* 2005, **24**(20):3624-34, Epub 2005 Sep 29.
70. Dahms SO, et al: Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. *Proc Natl Acad Sci USA* 2010, **107**(12):5381-6.
71. Munter LM, et al: GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. *EMBO Journal* 2007, **26**(6):1702-12.
72. Kienlen-Campard P, et al: Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. *J Biol Chem* 2008, **283**(12):7733-44.
73. Eggert S, et al: Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production. *J Biol Chem* 2009, **284**(42):28943-52.
74. Kaden D, et al: Subcellular localization and dimerization of APLP1 are strikingly different from APP and APLP2. *J Cell Sci* 2009, **122**(Pt 3):368-77.
75. Ghiso J, et al: A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion. *Biochem J* 1992, **288**(Pt 3):1053-9.
76. Storey E, et al: The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites. *Brain Res* 1996, **735**(1):59-66.
77. Yamazaki T, Koo EH, Selkoe DJ: Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. *J Neurosci* 1997, **17**(3):1004-10.
78. Young-Pearse TL, et al: Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. *Neural Dev* 2008, **3**:15.
79. Young-Pearse TL, et al: A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. *J Neurosci* 2007, **27**(52):14459-69.
80. Wang Z, et al: Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. *J Neurosci* 2009, **29**(35):10788-801.
81. Scheiffele P, et al: Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. *Cell* 2000, **101**(6):657-69.
82. Graf ER, et al: Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. *Cell* 2004, **119**(7):1013-26.
83. Biederer T, et al: SynCAM, a synaptic adhesion molecule that drives synapse assembly. *Science* 2002, **297**(5586):1525-31.
84. Fogel AI, et al: SynCAMs organize synapses through heterophilic adhesion. *J Neurosci* 2007, **27**(46):12516-30.
85. Sara Y, et al: Selective capability of SynCAM and neuroligin for functional synapse assembly. *J Neurosci* 2005, **25**(1):260-70.
86. Linhoff MW, et al: An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. *Neuron* 2009, **61**(5):734-49.
87. Dalva MB, McClelland AC, Kayser MS: Cell adhesion molecules: signalling functions at the synapse. *Nat Rev Neurosci* 2007, **8**(3):206-20, Epub 2007 Feb 14.
88. Norstrom EM, et al: Identification of NEEP21 as a ss-amyloid precursor protein-interacting protein in vivo that modulates amyloidogenic processing in vitro. *J Neurosci* 30(46):15677-85.
89. Mattson MP: Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. *Physiol Rev* 1997, **77**(4):1081-132.
90. Reinhard C, Hebert SS, De Strooper B: The amyloid-beta precursor protein: integrating structure with biological function. *Embo J* 2005, **24**(23):3996-4006, Epub 2005 Oct 27.
91. Koo EH, et al: Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. *Proc Natl Acad Sci USA* 1990, **87**(4):1561-5.
92. Yamazaki T, Selkoe DJ, Koo EH: Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. *J Cell Biol* 1995, **129**(2):431-42.
93. Lyckman AW, et al: Post-translational processing and turnover kinetics of presynaptically targeted amyloid precursor superfamily proteins in the central nervous system. *J Biol Chem* 1998, **273**(18):11100-6.
94. Moya KL, et al: The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. *Dev Biol* 1994, **161**(2):597-603.
95. Hung AY, et al: Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. *Proc Natl Acad Sci USA* 1992, **89**(20):9439-43.
96. Bibel M, et al: Differentiation of mouse embryonic stem cells into a defined neuronal lineage. *Nat Neurosci* 2004, **7**(9):1003-9.
97. Murakami N, et al: Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus. *J Neurotrauma* 1998, **15**(11):993-1003.
98. Van den Heuvel C, et al: Upregulation of amyloid precursor protein messenger RNA in response to traumatic brain injury: an ovine head impact model. *Exp Neurol* 1999, **159**(2):441-50.
99. Leyssen M, et al: Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. *Embo J* 2005, **24**(16):2944-55, Epub 2005 Jul 28.
100. Rossjohn J, et al: Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. *Nat Struct Biol* 1999, **6**(4):327-31.
101. Saitoh T, et al: Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. *Cell* 1989, **58**(4):615-22.
102. Ninomiya H, et al: Amino acid sequence RERMS represents the active domain of amyloid beta/A4 protein precursor that promotes fibroblast growth. *J Cell Biol* 1993, **121**(4):879-86.
103. Meziane H, et al: Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnesic mice. *Proc Natl Acad Sci USA* 1998, **95**(21):12683-8.
104. Roch JM, et al: Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. *Proc Natl Acad Sci USA* 1994, **91**(16):7450-4.
105. Thornton E, et al: Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. *Brain Res* 2006, **1094**(1):38-46.
106. Copanaki E, et al: sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. *Mol Cell Neurosci* 2010, **44**(4):386-93.
107. Allinquant B, et al: Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. *J Cell Biol* 1995, **128**(5):919-27.
108. Perez RG, et al: The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. *J Neurosci* 1997, **17**(24):9407-14.
109. Herard AS, et al: siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. *Neurobiol Aging* 2006, **27**(12):1740-50.
110. Taylor CJ, et al: Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. *Neurobiol Dis* 2008, **31**(2):250-60.
111. Han P, et al: Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. *J Neurosci* 2005, **25**(50):11542-52.
112. Caille I, et al: Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. *Development* 2004, **131**(9):2173-81, Epub 2004 Apr 8.
113. Gakhar-Koppole N, et al: Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. *Eur J Neurosci* 2008, **28**(5):871-82.
114. Bergmann BA, et al: Neurons generated from APP/APLP1/APLP2 triple knockout embryonic stem cells behave normally in vitro and in vivo: lack of evidence for a cell autonomous role of the amyloid precursor protein in neuronal differentiation. *Stem Cells* 2010, **28**(3):399-406.
115. Naumann N, et al: Transgenic expression of human wild-type amyloid precursor protein decreases neurogenesis in the adult hippocampus. *Hippocampus* 20(8):971-9.
116. Li H, et al: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. *Proc Natl Acad Sci USA* 107(40):17362-7.
117. Schwarzman AL, et al: Transthyretin sequesters amyloid beta protein and prevents amyloid formation. *Proc Natl Acad Sci USA* 1994, **91**(18):8368-72.

118. Choi SH, *et al*: Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). *Journal of Neuroscience* 2007, **27**(26):7006-10.
119. Buxbaum JN, *et al*: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. *Proceedings of the National Academy of Sciences of the United States of America* 2008, **105**(7):2681-6.
120. Kuro-o M, *et al*: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature* 1997, **390**(6655):45-51.
121. Kurosu H, *et al*: Suppression of aging in mice by the hormone Klotho. *Science* 2005, **309**(5742):1829-33.
122. Imura A, *et al*: alpha-Klotho as a regulator of calcium homeostasis. *Science* 2007, **316**(5831):1615-8.
123. Lannfelt L, *et al*: Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. *Neurosci Lett* 1995, **199**(3):203-6.
124. Sennvik K, *et al*: Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. *Neurosci Lett* 2000, **278**(3):169-72.
125. Colciaghi F, *et al*: [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. *Mol Med* 2002, **8**(2):67-74.
126. Tyler SJ, *et al*: alpha- and beta-secretase: profound changes in Alzheimer's disease. *Biochem Biophys Res Commun* 2002, **299**(3):373-6.
127. Roe CM, *et al*: Cancer linked to Alzheimer disease but not vascular dementia. *Neurology* 74(2):106-12.
128. Venkataramani V, *et al*: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the Alzheimer amyloid precursor protein. *J Biol Chem* 285(14):10678-89.
129. Turner PR, *et al*: Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Prog Neurobiol* 2003, **70**(1):1-32.
130. Nikolaev A, McLaughlin T, O'Leary DDM, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* 2009, **457**:981-990.
131. Suzuki T, Nakaya T: Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. *J Biol Chem* 2008, **283**(44):29633-7.
132. Iijima K, *et al*: Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. *J Neurochem* 2000, **75**(3):1085-91.
133. Kimberly WT, *et al*: Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. *J Neurosci* 2005, **25**(23):5533-43.
134. Muresan Z, Muresan V: c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. *J Neurosci* 2005, **25**(15):3741-51.
135. Scheinfeld MH, *et al*: Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. *J Biol Chem* 2003, **278**(43):42058-63.
136. Ando K, *et al*: Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation. *J Neurosci* 1999, **19**(11):4421-7.
137. Muresan Z, Muresan V: Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. *J Cell Biol* 2005, **171**(4):615-25.
138. Lee MS, *et al*: APP processing is regulated by cytoplasmic phosphorylation. *J Cell Biol* 2003, **163**(1):83-95.
139. Ando K, *et al*: Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. *J Biol Chem* 2001, **276**(43):40353-61.
140. Tamayev R, Zhou D, D'Adamio L: The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. *Mol Neurodegener* 2009, **4**:28.
141. Taru H, Suzuki T: Facilitation of stress-induced phosphorylation of beta-amyloid precursor protein family members by X11-like/Mint2 protein. *J Biol Chem* 2004, **279**(20):21628-36.
142. Pastorino L, *et al*: The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. *Nature* 2006, **440**(7083):528-34.
143. Lu PJ, *et al*: The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature* 1999, **399**(6738):784-8.
144. Sano Y, *et al*: Physiological mouse brain Abeta levels are not related to the phosphorylation state of threonine-668 of Alzheimer's APP. *PLoS One* 2006, **1**:e51.
145. Koo EH: The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? *Traffic* 2002, **3**(11):763-70.
146. King GD, Turner SR: Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? *Exp Neurol* 2004, **185**(2):208-19.
147. Barbagallo AP, *et al*: Tyr(682) in the intracellular domain of APP regulates amyloidogenic APP processing in vivo. *PLoS One* 5(11):e15503.
148. Pietrzik CU, *et al*: FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. *J Neurosci* 2004, **24**(17):4259-65.
149. Yankner BA, *et al*: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. *Science* 1989, **245**(4916):417-20.
150. Oster-Granite ML, *et al*: Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. *J Neurosci* 1996, **16**(21):6732-41.
151. Neve RL, *et al*: Transgenic mice expressing APP-C100 in the brain. *Neurobiol Aging* 1996, **17**(2):191-203.
152. Cupers P, *et al*: The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. *J Neurochem* 2001, **78**(5):1168-78.
153. Kimberly WT, *et al*: The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. *J Biol Chem* 2001, **276**(43):40288-92.
154. Passer B, *et al*: Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. *J Alzheimers Dis* 2000, **2**(3-4):289-301.
155. Kinoshita A, *et al*: The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. *J Biol Chem* 2002, **277**(32):28530-6.
156. Chang KA, Suh YH: Possible roles of amyloid intracellular domain of amyloid precursor protein. *BMB Rep* 43(10):656-63.
157. Gao Y, Pimplikar SW: The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. *Proc Natl Acad Sci USA* 2001, **98**(26):14979-84.
158. Ryan KA, Pimplikar SW: Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. *J Cell Biol* 2005, **171**(2):327-35, Epub 2005 Oct 17.
159. Gillberto L, *et al*: Transgenic Expression of the Amyloid-beta Precursor Protein-Intracellular Domain Does Not Induce Alzheimer's Disease-Like Traits In Vivo. *PLoS One* 5(7):e11609.
160. Ghosal K, *et al*: Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. *Proc Natl Acad Sci USA* 2009, **106**(43):18367-72.
161. Lu DC, *et al*: A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. *Nat Med* 2000, **6**(4):397-404.
162. Bertrand E, *et al*: A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. *Mol Cell Neurosci* 2001, **18**(5):503-11.
163. Galvan V, *et al*: Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. *Proc Natl Acad Sci USA* 2006, **103**(18):7130-5, Epub 2006 Apr 25.
164. Saganich MJ, *et al*: Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. *J Neurosci* 2006, **26**(52):13428-36.
165. Park SA, *et al*: Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. *Biochem Biophys Res Commun* 2009, **388**(2):450-5.
166. Harris JA, *et al*: Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. *J Neurosci* 30(1):372-81.
167. Bredesen DE, John V, Galvan V: Importance of the caspase cleavage site in amyloid-beta protein precursor. *J Alzheimers Dis* 22(1):57-63.
168. De Strooper B, Annaert W: Novel research horizons for presenilins and gamma-secretases in cell biology and disease. *Annu Rev Cell Dev Biol* 26:235-60.

169. Goodger ZV, et al: Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. *J Cell Sci* 2009, **122**(Pt 20):3703-14.
170. Sala Frigerio C, et al: beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. *FEBS J* 277(6):1503-18.
171. Cao X, Sudhof TC: A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science* 2001, **293**(5527):115-20.
172. Scheinfeld MH, Matsuda S, D'Adamo L: JNK-interacting protein-1 promotes transcription of A beta protein precursor but not A beta precursor-like proteins, mechanistically different than Fe65. *Proc Natl Acad Sci USA* 2003, **100**(4):1729-34.
173. Cao X, Sudhof TC: Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. *J Biol Chem* 2004, **279**(23):24601-11, Epub 2004 Mar 24.
174. Hass MR, Yankner BA: A gamma-secretase-independent mechanism of signal transduction by the amyloid precursor protein. *J Biol Chem* 2005, **280**(44):36895-904, Epub 2005 Aug 15.
175. Yang Z, et al: A dominant role for FE65 (APBB1) in nuclear signaling. *J Biol Chem* 2006, **281**(7):4207-14, Epub 2005 Dec 6.
176. Giliberto L, et al: Evidence that the Amyloid beta Precursor Protein-intracellular domain lowers the stress threshold of neurons and has a "regulated" transcriptional role. *Mol Neurodegener* 2008, **3**:12.
177. Baek SH, et al: Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. *Cell* 2002, **110**(1):55-67.
178. Kim HS, et al: C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. *FASEB J* 2003, **17**(13):1951-3.
179. Pardossi-Piquard R, et al: Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. *Neuron* 2005, **46**(4):541-54.
180. Zhang YW, et al: Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. *Proc Natl Acad Sci USA* 2007, **104**(25):10613-8, Epub 2007 Jun 7.
181. Checler F, et al: The gamma/epsilon-secretase-derived APP intracellular domain fragments regulate p53. *Current Alzheimer Research* 2007, **4**(4):423-6.
182. Liu Q, et al: Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1. *Neuron* 2007, **56**(1):66-78.
183. von Rotz RC, et al: The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. *J Cell Sci* 2004, **117**(Pt 19):4435-48.
184. Leissring MA, et al: A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. *Proc Natl Acad Sci USA* 2002, **99**(7):4697-702.
185. Muller T, et al: Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). *Mol Biol Cell* 2007, **18**(1):201-10.
186. Hebert SS, et al: Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. *EMBO Rep* 2006, **7**(7):739-45, Epub 2006 May 19.
187. Chen AC, Selkoe DJ: Response to: Pardossi-Piquard et al., "Presenilin-Dependent Transcriptional Control of the Abeta-Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP." *Neuron* 46, 541-554. *Neuron* 2007, **53**(4):479-83.
188. Repetto E, et al: Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. *Journal of Biological Chemistry* 2007, **282**(43):31504-16.
189. Tamboli IY, et al: Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. *J Neurosci* 2008, **28**(46):12097-106.
190. Waldron E, et al: Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. *Exp Cell Res* 2008, **314**(13):2419-33.
191. Hornsten A, et al: APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. *Proc Natl Acad Sci USA* 2007, **104**(6):1971-6, Epub 2007 Jan 31.
192. Wiese M, Antebi A, Zheng H: Intracellular trafficking and synaptic function of APL-1 in Caenorhabditis elegans. *PLoS One* 5(9).
193. Li H, et al: Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis. *J Biol Chem* 285(40):30598-605.
194. Gunawardena S, Goldstein LS: Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. *Neuron* 2001, **32**(3):389-401.
195. Torroja L, et al: Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport. *Curr Biol* 1999, **9**(9):489-92.
196. Kamal A, et al: Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. *Nature* 2001, **414**(6864):643-8.
197. Satpute-Krishnan P, DeGiorgis JA, Bearer EL: Fast anterograde transport of herpes simplex virus: role for the amyloid precursor protein of alzheimer's disease. *Aging Cell* 2003, **2**(6):305-18.
198. Satpute-Krishnan P, et al: A peptide zipcode sufficient for anterograde transport within amyloid precursor protein. *Proc Natl Acad Sci USA* 2006, **103**(44):16532-7, Epub 2006 Oct 24.
199. Lazarov O, et al: Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. *J Neurosci* 2005, **25**(9):2386-95.
200. Torroja L, Luo L, White K: APPL, the Drosophila member of the APP-family, exhibits differential trafficking and processing in CNS neurons. *J Neurosci* 1996, **16**(15):4638-50.
201. Ashley J, et al: Fasciclin II signals new synapse formation through amyloid precursor protein and the scaffolding protein dx11/Mint. *J Neurosci* 2005, **25**(25):5943-55.
202. Fossgreen A, et al: Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. *Proc Natl Acad Sci USA* 1998, **95**(23):13703-8.
203. Merdes G, et al: Interference of human and Drosophila APP and APP-like proteins with PNS development in Drosophila. *Embo J* 2004, **23**(20):4082-95.
204. Muller U, et al: Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. *Cell* 1994, **79**(5):755-65.
205. Zheng H, et al: beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. *Cell* 1995, **81**(4):525-31.
206. Li ZW, et al: Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells. *Proc Natl Acad Sci USA* 1996, **93**(12):6158-62.
207. Ring S, et al: The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. *J Neurosci* 2007, **27**(29):7817-26.
208. Magara F, et al: Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid-precursor protein. *Proc Natl Acad Sci USA* 1999, **96**(8):4656-61.
209. Steinbach JP, et al: Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. *Cell Death Differ* 1998, **5**(10):858-66.
210. Phinney AL, et al: No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. *Neuroscience* 1999, **90**(4):1207-16.
211. Priller C, et al: Synapse formation and function is modulated by the amyloid precursor protein. *J Neurosci* 2006, **26**(27):7212-21.
212. Bittner T, et al: Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. *J Neurosci* 2009, **29**(33):10405-9.
213. Lee KJ, et al: Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. *Neuroscience* 169(1):344-56.
214. Dawson GR, et al: Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. *Neuroscience* 1999, **90**(1):1-13.
215. Seabrook GR, et al: Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. *Neuropharmacology* 1999, **38**(3):349-59.
216. Yang L, et al: Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. *J Neurosci* 2009, **29**(50):15660-8.

217. Santos SF, *et al*: Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. *J Neurosci* 2009, **29**(15):4708-18.
218. Yang L, *et al*: Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses. *Neuroscience* 2007, **149**(4):768-78, Epub 2007 Aug 28.
219. von Koch CS, *et al*: Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. *Neurobiol Aging* 1997, **18**(6):661-9.
220. Heber S, *et al*: Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. *J Neurosci* 2000, **20**(21):7951-63.
221. Wang P, *et al*: Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. *J Neurosci* 2005, **25**(5):1219-25.
222. Yang G, *et al*: Reduced synaptic vesicle density and active zone size in mice lacking amyloid precursor protein (APP) and APP-like protein 2. *Neurosci Lett* 2005, **384**(1-2):66-71.
223. Wang B, *et al*: Amyloid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. *Proc Natl Acad Sci USA* 2007, **104**:14140-14145.
224. Herms J, *et al*: Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. *Embo J* 2004, **23**(20):4106-15.
225. Guenette S, *et al*: Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. *Embo J* 2006, **25**(2):420-31, Epub 2006 Jan 12.
226. Lambert de Rouvroit C, Goffinet AM: Neuronal migration. *Mech Dev* 2001, **105**(1-2):47-56.
227. Ring S, *et al*: The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. *J Neurosci* 2007, **27**(29):7817-26.
228. Barbagallo AP, *et al*: A single tyrosine residue in the amyloid precursor protein intracellular domain is essential for developmental function. *J Biol Chem* .

doi:10.1186/1750-1326-6-27

Cite this article as: Zheng and Koo: Biology and pathophysiology of the amyloid precursor protein. *Molecular Neurodegeneration* 2011 **6**:27.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

